Date: 2012-12-20
Type of information: Licensing agreement
Compound: CAP-T™ and CAP® cell expression systems
Company: CEVEC Pharmaceuticals (Germany) Yuhan Corporation (South Korea)
Therapeutic area:
Type agreement: licensing
Action mechanism: CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.
Disease:
Details: CEVEC Pharmaceuticals, a developer of a novel human expression system derived from amniocytes, and Yuhan Corporation, a leading manufacturer of pharmaceutical products based in Seoul, South Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
Financial terms:
Latest news:
